Direct comparison of insulin lispro and aspart shows small differences in plasma insulin profiles after subcutaneous injection in type 1 diabetes

被引：52

作者：

Hedman, CA

Lindstrom, T

Arnqvist, HJ

机构：

[1] Linkoping Univ, Dept Med & Care, Div Internal Med, Linkoping, Sweden

[2] Linkoping Univ, Fac Hlth Sci, Dept Biomed & Surg, Div Cellbiol, Linkoping, Sweden

来源：

DIABETES CARE | 2001年 / 24卷 / 06期

关键词：

D O I：

10.2337/diacare.24.6.1120

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1120 / 1121

页数：2

共 50 条

[31] COMPARISON OF PLASMA-INSULIN PROFILES AFTER SUBCUTANEOUS ADMINISTRATION OF INSULIN BY JET SPRAY AND CONVENTIONAL NEEDLE INJECTION IN PATIENTS WITH INSULIN-DEPENDENT DIABETES-MELLITUS
PEHLING, GB
GERICH, JE
MAYO CLINIC PROCEEDINGS, 1984, 59 (11) : 751 - 754
[32] A comparison of the rapid-acting insulin analogue glulisine with lispro and aspart for the pump treatment of patients with type 1 diabetes
Peter Bramlage
Sascha R. Tittel
Silvia Müther
Birgit Reinhart-Steininger
Holger Haberland
Semik Khodaverdi
Stefan Zimny
Ute Ohlenschläger
Stefanie Lanzinger
Thomas Haak
Acta Diabetologica, 2022, 59 : 1453 - 1460
[33] Type 1 diabetes patients can temporarily switch from continuous subcutaneous insulin infusion with insulin aspart to basal bolus therapy with insulin aspart and insulin glargine
Bode, B
Hirsch, I
Hu, P
Santiago, O
DIABETES, 2003, 52 : A102 - A102
[34] Insulin aspart compared to regular insulin and insulin lispro in basal bolus therapy with NPH to treat pediatric patients with type 1 diabetes mellitus
Arslanian, S
Foster, C
Wright, NM
Stender, S
Hales, P
Hale, D
DIABETOLOGIA, 2005, 48 : A327 - A327
[35] External continuous subcutaneous infusion of insulin using insulin aspart (NovoLog®) in subjects with type 1 and type 2 diabetes
Schorr, Alan
Wittlin, Steven
Weng, Wayne
Howard, Campbell
DIABETES, 2006, 55 : A457 - A457
[36] Continuous subcutaneous insulin infusion (CSII)of insulin aspart versus multiple daily injection of insulin aspart/insulin glargine in type 1 diabetic patients previously treated with CSII
Hirsch, IB
Bode, BW
Garg, S
Lane, WS
Süssman, A
Hu, P
Santiago, OM
Kolaczynski, J
DIABETES CARE, 2005, 28 (03) : 533 - 538
[37] Pump compatibility of insulin aspart compared to insulin lispro with respect to catheter complications and dermal/subcutaneous irritations in type I diabetes patients with insulin pump therapy (CSII)
Siegmund, T
von Amelunxen, S
Kaiser, M
Schumm-Draeger, PM
DIABETOLOGIA, 2005, 48 : A299 - A299
[38] A comparison of pharmocodynamics and pharmacokinetics of Biphasic Insulin Aspart 30, 50, 70 & Pure Insulin Aspart in type 1 diabetes
Thorisdottir, Rannveig L.
Parkner, Tina
Chen, Jian-Wen
Ejskjaer, Niels
Christiansen, Jens S.
DIABETES, 2007, 56 : A555 - A555
[39] Reduced hypoglycaemia is observed with inhaled insulin versus subcutaneous insulin aspart in patients with type 1 diabetes mellitus
Nikonova, E.
Bode, B.
Gill, J.
Stewart, J.
Blonde, L.
DIABETOLOGIA, 2015, 58 : S449 - S450
[40] Immune responses to insulin aspart and biphasic insulin aspart in people with type 1 and type 2 diabetes
Lindholm, A
Jensen, LB
Home, PD
Raskin, P
Boehm, BO
Råstam, J
DIABETES CARE, 2002, 25 (05) : 876 - 882

← 1 2 3 4 5 →